Analytical method for increasing susceptibility of sorafenib treatment in hepatocellular carcinoma

摘要

The present invention provides an analysis method for providing information necessary for diagnosis of hepatocellular tumor patients with sensitivity to sorafenib. When analyzing the expression levels of 8 genes, i.e., CDH1, CHAD, EFNA2, FANCC, MAP2K1, MEN1, PBRM1, and PPARG genes in tumor tissues of hepatocellular tumor patients, the response (susceptibility) to sorafenib with high accuracy It has been found by the present invention that it is predictable. Therefore, the combination of the above genes can be usefully used as a biomarker capable of selecting hepatocellular tumor patients with sensitivity to sorafenib.